Atom Investors LP Seres Therapeutics, Inc. Transaction History

Atom Investors LP

$782 Million
Q1 2024

A detailed history of Atom Investors LP transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Atom Investors LP holds 103,316 shares of MCRB stock, worth $74,387. This represents 0.01% of its overall portfolio holdings.

Number of Shares

103,316

Holding current value

$74,387

% of portfolio

0.01%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.75 - $1.56 $77,487 - $161,172	103,316 New	103,316 $79,000
Q1 2023 May 15, 2023	SELL	$4.95 - $6.09 $25,403 - $31,253	-5,132 Reduced 5.37%	90,388 $512,000
Q4 2022 Feb 14, 2023	SELL	$5.09 - $9.05 $67,697 - $120,365	-13,300 Reduced 12.22%	95,520 $534,000
Q3 2022 Nov 08, 2022	SELL	$3.5 - $7.2 $290,983 - $598,593	-83,138 Reduced 43.31%	108,820 $699,000
Q2 2022 Aug 15, 2022	BUY	$2.7 - $7.62 $410,324 - $1.16 Million	151,972 Added 380.06%	191,958 $658,000

Q1 2022 May 16, 2022	SELL	$6.3 - $8.84 $258,974 - $363,385	-41,107 Reduced 50.69%	39,986 $285,000
Q4 2021 Feb 14, 2022	BUY	$6.02 - $11.43 $488,179 - $926,892	81,093 New	81,093 $676,000

Others Institutions Holding MCRB

# of Institutions

100

Shares Held

62.7M

Call Options Held

36.9K

Put Options Held

476K

Flagship Pioneering Inc. Cambridge, MA

23.1M
Shares

$16.6 Million
1.17% of portfolio
Black Rock Inc. New York, NY

6.83M
Shares

$4.91 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.73M
Shares

$4.85 Million
0.0% of portfolio
Hudson Bay Capital Management LP Greenwich, CT

5.43M
Shares

$3.91 Million
0.03% of portfolio
Geode Capital Management, LLC Boston, MA

2.13M
Shares

$1.54 Million
0.0% of portfolio

View Full List

About Seres Therapeutics, Inc.

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

More about MCRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Atom Investors LP with notifications on news.

Account